Across TCGA pan-cancer cohorts, HBG2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated HBG2 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher HBG2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated HBG2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where HBG2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	IV	1.000	0.105	.024	13	view →
PDAC	OS	Median	III,IV	0.693	0.200	.030	4	view →
LUAD	DFS	Tertile	All	1.000	0.662	.026	4	view →
HNSC	OS	Tertile	All	0.952	1.000	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: HBG2 tumor-vs-normal RNA expression · all HBG2 data types